시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 미생물 발효 기술 시장
Microbial Fermentation Technology
상품코드 : 1594923
리서치사 : Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일 : 2024년 11월
페이지 정보 : 영문 324 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,850 ￦ 8,401,000
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 ￦ 25,205,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.


한글목차

세계의 미생물 발효 기술 시장은 2030년까지 452억 달러에 도달

2023년에 315억 달러로 추정되는 세계의 미생물 발효 기술 시장은 2023-2030년 CAGR 5.3%로 성장하며, 2030년에는 452억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 항생제 용도는 CAGR 7.5%를 기록하며, 분석 기간 종료시에는 162억 달러에 달할 것으로 예측됩니다. 효소 용도의 성장률은 분석 기간 중 CAGR 3.4%로 추정됩니다.

미국 시장은 85억 달러로 추정, 중국은 CAGR 9.2%로 성장할 것으로 예측

미국의 미생물 발효 기술 시장은 2023년에 85억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 102억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 9.2%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.5%와 4.4%로 예측됩니다. 유럽에서는 독일이 CAGR 3.4%로 성장할 것으로 예측됩니다.

세계의 미생물 발효 기술 시장 - 주요 동향과 촉진요인 정리

미생물 발효 기술이란 무엇이며, 왜 현대 바이오테크놀러지에서 중요한가?

미생물 발효 기술은 박테리아, 효모, 균류 등의 미생물을 사용하여 발효를 통해 원료를 가치 있는 제품으로 전환하는 생물학적 과정입니다. 이 기술은 통제된 조건에서 미생물의 대사 활동을 이용하여 의약품, 효소, 바이오연료, 아미노산, 유기산, 항생제, 프로바이오틱스 등 다양한 생물학적 제품을 생산합니다. 발효는 배치 발효, 연속발효, 공급 배치발효 등다양한 형태로 이루어지며, 각기 다른 생산 규모와 제품 유형에 적합합니다.

미생물 발효 기술의 중요성은 화학적 합성이 어려운 고부가가치, 지속가능한, 종종 복잡한 생체 분자를 생산할 수 있는 능력에 있습니다. 인슐린과 백신에서 바이오연료와 식품첨가제까지 모든 것을 생산할 수 있으며, 현대 생명공학, 제약, 식품 및 음료 산업, 농업의 근간이 되고 있습니다. 지속가능한 생산 방식에 대한 전 세계적인 수요가 증가함에 따라 미생물 발효는 다양한 산업에서 필수적인 제품을 생산할 수 있는 보다 친환경적이고 효율적인 대안을 제공합니다.

기술의 발전은 어떻게 미생물 발효 기술 시장을 형성하고 있는가?

기술의 발전은 미생물 발효 기술의 효율성, 확장성 및 다양성을 크게 향상시켜 다양한 용도에서 혁신을 촉진하고 있습니다. 주요 발전 중 하나는 유전자공학과 합성생물학학의 부상입니다. 연구자들은 미생물의 유전자 경로를 조작하여 의약품, 효소, 바이오연료 및 기타 생체 분자의 생산량을 늘릴 수 있습니다. 또한 이러한 조작된 균주는 이전에는 달성할 수 없었던 새로운 화합물을 생산할 수 있으며, 신약 개발 및 산업 생명 공학에서 미생물 발효의 응용 가능성을 넓히고 있습니다.

첨단 바이오리액터개발로 미생물 발효 능력이 더욱 향상되었습니다. 최신 바이오리액터는 온도, pH, 산소 수준, 영양 공급과 같은 매개 변수를 조정하는 자동 제어 시스템을 갖추고 있으며, 미생물의 최적의 성장 조건을 보장합니다. 연속식흐름 바이오리액터 및무세포시스템과 같은 기술 혁신은 생산 효율을 높이고, 가동 중지 시간을 줄이며, 더 높은 생산성과 확장성을 달성할 수 있게 합니다. 이러한 바이오리액터는 다양한 미생물 배양에 적응할 수 있으며, 다양한 생체 분자를 유연하게 생산할 수 있습니다.

대사체학, 유전체학, 생물정보학의 발전도 미생물 발효 기술을 형성하고 있습니다. 대사 공학 기술은 미생물의 대사 경로를 미세 조정하여 기질에서 목표 제품으로의 전환 효율을 높일 수 있습니다. 유전체학 및 생물정보학은 미생물의 DNA에 대한 인사이트을 제공하고 생합성을 담당하는 유전자 클러스터를 식별할 수 있게 합니다. 이는 균주 개선, 더 빠른 공정 최적화, 새로운 발효 기반 제품 개발에 도움이 될 수 있습니다. 또한 CRISPR-Cas9 유전자 편집 기술을 통해 특정 발효 공정에 맞는 맞춤형 균주 제작을 가속화하여 제품 수율을 향상시키고 생산 비용을 절감할 수 있습니다. 이러한 기술 혁신은 미생물 발효 능력을 확장할 뿐만 아니라 정밀 생명 공학, 지속가능한 제조, 다양한 산업 분야의 효율적인 생산과 같은 광범위한 동향과도 일치합니다.

다양한 분야에서의 미생물 발효 기술의 새로운 응용 사례는?

미생물 발효 기술은 복잡한 생체 분자를 지속적으로 생산할 필요가 있으므로 광범위한 분야에서 응용되고 있습니다. 제약업계에서는 항생제, 백신, 인슐린 및 기타 치료용 단백질 생산에 미생물 발효가 사용되고 있습니다. 미생물 발효는 당뇨병, 암, 자가면역질환 등 치료에 필수적인 생물학적 제제 및 바이오시밀러의 대량 생산을 지원하고 있습니다. 발효를 기반으로 한 의약품 생산은 높은 순도, 일관성 및 확장성을 보장하므로 많은 제약회사들이 선호하는 방법입니다.

음료 및 식품 산업에서미생물 발효는 아미노산, 유기산(구연산, 젖산 등), 비타민, 프로바이오틱스와 같은 식품 성분을 생산하는 데 널리 사용됩니다. 이러한 생물 생산물은 식품의 영양가, 풍미 및 보존성을 향상시킵니다. 발효는 또한 요구르트, 치즈, 맥주, 콤부차와 같은 발효 식품 생산의 핵심으로 건강하고 기능적인 식품에 대한 수요 증가를 지원하고 있습니다. 또한 식물성 대체 육류에 발효를 활용하면 동물성 식품과 유사한 단백질, 풍미, 질감을 만들어낼 수 있으며, 지속가능한 식습관의 부상을 지원할 수 있는 방법으로 각광을 받고 있습니다.

바이오연료산업은 미생물 발효를 통해 옥수수, 사탕수수, 농업 잔류물 등 재생한 바이오매스 자원에서 바이오 에탄올, 바이오 부탄올 및 기타 바이오연료를 생산하고 있습니다. 이 공정은 화석연료를 대체할 수 있는 지속가능한 대체 연료를 제공하고 온실 가스 배출을 줄이며 에너지 자립을 지원합니다. 농업분야에서는 발효 기술이 바이오 농약, 바이오 비료, 사료첨가제 생산에 적용되어 화학물질 투입으로 인한 환경 영향을 줄이면서 작물 수확량과 가축의 건강을 개선하고 있습니다. 이러한 분야에서의 미생물 발효의 적용 확대는 산업 및 소비자 제품 모두에서 지속가능하고 효율적이며 확장 가능한 생산 공정을 가능하게 하는 데 있으며, 미생물 발효의 중요한 역할을 강조하고 있습니다.

미생물 발효 기술 시장의 성장 원동력은?

미생물 발효 기술 시장의 성장은 지속가능한 생산 방식에 대한 수요 증가, 의료 분야에서 생물학적 제제의 보급률 증가, 유전공학의 발전 등 여러 가지 요인에 의해 이루어지고 있습니다. 주요 성장 요인 중 하나는 전 세계에서 산업 전반에 걸쳐 지속가능한 생산이 추진되고 있다는 점입니다. 기업과 정부가 탄소발자국을 줄이기 위해 노력하는 가운데, 미생물 발효는 기존의 화학 합성 및 석유화학 기반 공정에 대한 보다 친환경적인 대안을 제시합니다. 재생한 원료로부터 고부가가치 생체 분자를 생산할 수 있는 능력은 순환 경제 모델에 부합하며 식품, 농업, 에너지 등의 분야에서 지속가능성 목표를 지원합니다.

헬스케어 분야에서의 생물학적 제제 및 바이오시밀러사용 확대는 미생물 발효 기술에 대한 수요를 더욱 촉진하고 있습니다. 백신, 단클론 항체, 치료용 단백질 등 생물학적 제제는 구조가 복잡하므로 주로 미생물 발효를 통해 생산됩니다. 전 세계 의료 시스템이 만성질환 치료를 위해 생물학적 제제에 대한 의존도가 높아짐에 따라 효율적이고 확장 가능한 발효 공정에 대한 수요가 급증하고 있습니다. 또한 바이오시밀러에 대한 정부 지원과 규제 당국의 승인은 발효 기반 제조 시설에 대한 투자를 촉진하고 시장 성장을 가속하고 있습니다.

합성 생물학 및 유전 공학의 발전도 미생물 발효 시장의 확대에 기여하고 있습니다. 더 높은 수율, 더 빠른 생산, 새로운 제품 합성을 위한 미생물 공학의 능력은 발효 기반 생산에 새로운 길을 열었습니다. 이로 인해 바이오 플라스틱, 특수 화학제품, 영양 보충제와 같은 혁신적인 제품이 개발되었습니다. 또한 유전체학기술(유전체학, 단백질학, 대사학)의 발전으로 균주 개발 및 발효 최적화가 개선되어 미생물 발효의 비용 효율성과 효율성이 향상되고 있습니다.

바이오프로세스 공학, 합성 생물학, 지속가능한 제조 방법의 혁신이 진행되면서 미생물 발효 기술 시장은 강력한 성장세를 보이고 있습니다. 이러한 추세는 재생하고 고부가가치이며 확장 가능한 바이오 제품에 대한 수요 증가와 함께 미생물 발효를 다양한 분야의 지속가능성, 효율성 및 세계 보건에 초점을 맞춘 현대 생명공학 전략에 필수적인 요소로 만들고 있습니다.

부문

용도(항생제, 효소, 재조합 단백질, 모노클로널 항체, 저분자화합물, 백신, 기타 용도), 최종 용도(연구개발·제조 수탁 기관(CDMO), 바이오 제약회사, 연구개발 수탁 기관(CRO), 학술·연구기관)

조사 대상 기업의 예(주목 44사)

  • Amyris, Inc.
  • Biocon Ltd.
  • BioVectra Inc.
  • Danone UK
  • F. Hoffmann-La Roche AG
  • Koninklijke DSM NV
  • Lonza Group AG
  • Novozymes A/S
  • TerraVia Holdings, Inc.
  • United Breweries Ltd.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA
영문 목차

영문목차

Global Microbial Fermentation Technology Market to Reach US$45.2 Billion by 2030

The global market for Microbial Fermentation Technology estimated at US$31.5 Billion in the year 2023, is expected to reach US$45.2 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Antibiotics Application, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$16.2 Billion by the end of the analysis period. Growth in the Enzymes Application segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.5 Billion While China is Forecast to Grow at 9.2% CAGR

The Microbial Fermentation Technology market in the U.S. is estimated at US$8.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Microbial Fermentation Technology Market - Key Trends & Drivers Summarized

What Is Microbial Fermentation Technology, and Why Is It So Crucial in Modern Biotechnology?

Microbial Fermentation Technology is a biological process that uses microorganisms like bacteria, yeast, and fungi to convert raw materials into valuable products through fermentation. This technology harnesses the metabolic activities of microbes under controlled conditions to produce a wide range of bioproducts, including pharmaceuticals, enzymes, biofuels, amino acids, organic acids, antibiotics, and probiotics. Fermentation can occur in various forms, such as batch, fed-batch, or continuous fermentation, each suited to different production scales and types of products.

The importance of microbial fermentation technology lies in its ability to produce high-value, sustainable, and often complex biomolecules that are challenging to synthesize chemically. It enables the production of everything from insulin and vaccines to biofuels and food additives, making it a cornerstone of modern biotechnology, pharmaceuticals, food and beverage industries, and agriculture. As global demand for sustainable production methods increases, microbial fermentation offers a greener, more efficient alternative for producing essential products across diverse industries.

How Are Technological Advancements Shaping the Microbial Fermentation Technology Market?

Technological advancements have significantly enhanced the efficiency, scalability, and versatility of Microbial Fermentation Technology, driving innovation across various applications. One of the major developments is the rise of genetic engineering and synthetic biology, which allows for the manipulation of microbial strains to produce higher yields of desired products. By modifying the genetic pathways of microorganisms, researchers can increase the production of pharmaceuticals, enzymes, biofuels, and other biomolecules. These engineered strains can also produce novel compounds that were previously unattainable, expanding the potential applications of microbial fermentation in drug discovery and industrial biotechnology.

The development of advanced bioreactors has further improved the capabilities of microbial fermentation. Modern bioreactors are equipped with automated control systems that regulate parameters like temperature, pH, oxygen levels, and nutrient supply, ensuring optimal growth conditions for microorganisms. Innovations like continuous-flow bioreactors and cell-free systems have enhanced production efficiency and reduced downtime, making it possible to achieve higher productivity and scalability. These bioreactors can be adapted for different microbial cultures, enabling flexible production of a wide range of biomolecules.

Advancements in metabolomics, genomics, and bioinformatics have also shaped microbial fermentation technology. Metabolic engineering techniques allow for fine-tuning the metabolic pathways of microorganisms, increasing the efficiency of substrate conversion into target products. Genomics and bioinformatics provide insights into microbial DNA, enabling the identification of gene clusters responsible for biosynthesis. This aids in strain improvement, faster process optimization, and the development of new fermentation-based products. Additionally, CRISPR-Cas9 gene-editing technology has accelerated the creation of custom strains tailored for specific fermentation processes, improving product yields and reducing production costs. These technological innovations not only expand the capabilities of microbial fermentation but also align with broader trends toward precision biotechnology, sustainable manufacturing, and efficient production in various industries.

What Are the Emerging Applications of Microbial Fermentation Technology Across Different Sectors?

Microbial Fermentation Technology is finding expanding applications across a wide range of sectors, driven by the need for sustainable production of complex biomolecules. In the pharmaceutical industry, microbial fermentation is used to produce antibiotics, vaccines, insulin, and other therapeutic proteins. It supports large-scale production of biologics and biosimilars, which are critical for treating diseases like diabetes, cancer, and autoimmune disorders. Fermentation-based production of drugs ensures high purity, consistency, and scalability, making it a preferred method for many pharmaceutical companies.

In the food and beverage industry, microbial fermentation is widely used to produce food ingredients, such as amino acids, organic acids (like citric acid and lactic acid), vitamins, and probiotics. These bioproducts enhance the nutritional value, flavor, and shelf-life of food products. Fermentation is also key to the production of fermented foods like yogurt, cheese, beer, and kombucha, supporting the growing demand for healthy and functional foods. Additionally, the use of fermentation in plant-based meat alternatives has gained traction, as it provides a way to create proteins, flavors, and textures that closely mimic animal products, supporting the rise of sustainable diets.

In the biofuel industry, microbial fermentation is used to produce bioethanol, biobutanol, and other biofuels from renewable biomass sources like corn, sugarcane, and agricultural residues. This process provides a sustainable alternative to fossil fuels, reducing greenhouse gas emissions and supporting energy independence. In the agricultural sector, fermentation technology is employed to produce biopesticides, biofertilizers, and animal feed additives, improving crop yields and livestock health while reducing the environmental impact of chemical inputs. The expanding applications of microbial fermentation across these sectors highlight its critical role in enabling sustainable, efficient, and scalable production processes in both industrial and consumer products.

What Drives Growth in the Microbial Fermentation Technology Market?

The growth in the Microbial Fermentation Technology market is driven by several factors, including increasing demand for sustainable production methods, rising prevalence of biologics in healthcare, and advancements in genetic engineering. One of the primary growth drivers is the global push for sustainable production across industries. As businesses and governments aim to reduce carbon footprints, microbial fermentation offers a greener alternative to traditional chemical synthesis and petrochemical-based processes. The ability to produce high-value biomolecules from renewable feedstocks aligns with the circular economy model, supporting sustainability goals in sectors like food, agriculture, and energy.

The growing use of biologics and biosimilars in the healthcare sector has further fueled demand for microbial fermentation technology. Biologics, which include vaccines, monoclonal antibodies, and therapeutic proteins, are primarily produced through microbial fermentation due to the complexity of their structures. As healthcare systems worldwide increase their reliance on biologics to treat chronic diseases, the demand for efficient and scalable fermentation processes has surged. Additionally, government support and regulatory approvals for biosimilars have driven investments in fermentation-based manufacturing facilities, boosting market growth.

Advancements in synthetic biology and genetic engineering have also contributed to the expansion of the microbial fermentation market. The ability to engineer microorganisms for higher yield, faster production, and novel product synthesis has opened new avenues for fermentation-based production. This has led to the development of innovative products like bio-based plastics, specialty chemicals, and nutraceuticals. Furthermore, advancements in omics technologies (genomics, proteomics, metabolomics) have improved strain development and fermentation optimization, making microbial fermentation more cost-effective and efficient.

With ongoing innovations in bioprocess engineering, synthetic biology, and sustainable manufacturing practices, the microbial fermentation technology market is poised for strong growth. These trends, combined with increasing demand for renewable, high-value, and scalable bioproducts, make microbial fermentation a vital component of modern biotechnology strategies focused on sustainability, efficiency, and global health across various sectors.

SCOPE OF STUDY:

The report analyzes the Microbial Fermentation Technology market in terms of US$ Million by the following Application; End-Use, and Geographic Regions/Countries:

Segments:

Application (Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines, Other Applications); End-Use (Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs), Academic & Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amyris, Inc.
  • Biocon Ltd.
  • BioVectra Inc.
  • Danone UK
  • F. Hoffmann-La Roche AG
  • Koninklijke DSM NV
  • Lonza Group AG
  • Novozymes A/S
  • TerraVia Holdings, Inc.
  • United Breweries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Microbial Fermentation Technology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Bio-based Products Spurs Adoption of Microbial Fermentation
    • Rising Use of Fermentation in Pharmaceutical Production Expands Market Scope
    • Growing Applications in Food and Beverages Set the Stage for Market Expansion
    • Regulatory Push for Sustainable Production Generates Demand for Fermentation Solutions
    • Growing Focus on Probiotics and Nutraceuticals Drives Fermentation Adoption
    • Use in Waste Treatment and Bioenergy Production Expands Addressable Market
    • Increasing Demand for Amino Acids Propels Fermentation Technology Market
    • Strong Growth in Bioplastics Market Generates Demand for Fermentation Technology
    • Rising Need for Organic Fertilizers Drives Adoption of Microbial Fermentation
    • Increasing Focus on Microbial Fermentation in Agriculture Spurs Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Microbial Fermentation Technology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Microbial Fermentation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Recombinant Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Recombinant Proteins by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Contract Development & Manufacturing Organizations (CDMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Contract Development & Manufacturing Organizations (CDMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Contract Development & Manufacturing Organizations (CDMOs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • JAPAN
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • CHINA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • EUROPE
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Microbial Fermentation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • FRANCE
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • GERMANY
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Microbial Fermentation Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • INDIA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: India 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Microbial Fermentation Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Microbial Fermentation Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Microbial Fermentation Technology by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030
  • AFRICA
    • Microbial Fermentation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Microbial Fermentation Technology by Application - Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Microbial Fermentation Technology by Application - Percentage Breakdown of Value Revenues for Antibiotics, Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes - Independent Analysis of Annual Revenues in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Microbial Fermentation Technology by End-Use - Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Microbial Fermentation Technology by End-Use - Percentage Breakdown of Value Revenues for Contract Development & Manufacturing Organizations (CDMOs), Biopharmaceutical Companies, Contract Research Organizations (CROs) and Academic & Research Institutes for the Years 2014, 2024 & 2030

IV. COMPETITION

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기